Global Recombinant Antihemophilic Globulin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Recombinant Antihemophilic Globulin Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
The recombinant antihemophilic globulin is a drug synthesized by gene recombination technology, which is used to treat patients with hemophilia A. Hemophilia A is an inherited bleeding disorder caused by deficiency or dysfunction of clotting factor VIII.
Recombinant Antihemophilic Globulin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Antihemophilic Globulin market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Clinical Treatment and Drug Research are the major drivers for the industry.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following stepsgene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Antihemophilic Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Segment by Type
Baikoc
Afstyla
Altuviiio
Clinical Treatment
Drug Research
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Antihemophilic Globulin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Antihemophilic Globulin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Antihemophilic Globulin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Antihemophilic Globulin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Antihemophilic Globulin introduction, etc. Recombinant Antihemophilic Globulin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Antihemophilic Globulin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Recombinant Antihemophilic Globulin report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Recombinant Antihemophilic Globulin market is projected to reach US$ million in 2029, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2029. Demand from Clinical Treatment and Drug Research are the major drivers for the industry.
The recombinant antihemophilic globulin is a synthetic form of factor VIII that functions similarly to the human-produced clotting factor VIII. It helps hemophilia A patients restore normal coagulation function and prevent or treat bleeding episodes by supplementing deficient coagulation factor VIII. The preparation process of the recombinant antihemophilic globulin includes the following stepsgene cloning, expression vector construction, cell culture and expression, purification and preparation. It has the characteristics of high efficiency, safety and stability, can effectively control and prevent bleeding, and improve the quality of life of hemophilia patients.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Recombinant Antihemophilic Globulin market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Shire (Baxter)
Bayer Healthcare
CSL
Pfizer
Grifols
Biogen
Octapharma
Novo Nordisk
Greencross
Kedrion
BPL
Hualan Bio
RAAS
Baxalta
Segment by Type
Baikoc
Afstyla
Altuviiio
Segment by Application
Clinical Treatment
Drug Research
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Colombia
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Recombinant Antihemophilic Globulin market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Recombinant Antihemophilic Globulin, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Recombinant Antihemophilic Globulin industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Recombinant Antihemophilic Globulin in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Recombinant Antihemophilic Globulin introduction, etc. Recombinant Antihemophilic Globulin Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Recombinant Antihemophilic Globulin market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices